Tag: HEME

FDX, STZ Recaps & More

Options Recaps 

Most of our luck with the options calls we made this week was good, with very few exceptions. We’re going to wrap up this short trading week by highlighted both of the fresh sets of ideas we formulated in yesterday morning’s premarket report.

We had signaled interest in the FDX 07/02 $149-155 Calls as well as the STZ 07/02 $175-180 Calls and in both cases we saw some really nice intraday movement:

FDX 07/02 $149-155 Calls
$149: 9.93-14.60 (+47%)
$150: 9.21-13.75 (+49%)
$152.50: 7.21-11.27 (+56%)
$155: 5.09-9.35 (+84%)
_____

STZ 07/02 $175-180 Calls
$175: 6.90-16.60 (+141%)
$177.50: 5.89-12.50 (+112%)
$180: 3.20-9.90 (+209%)

Fresh Options Ideas: 

We’ll close the week out with a wide range of ideas to follow, with both near and extended term expirations. For more quick strike opportunities we would first look to earnings play LNN, and to the SPY, with the markets ripping in early trading. For a longer-term track we have AVA and NWN, a couple of bottom-bouncers that are looking technically ripe for more prolonged increases.

LNN 07/17 $95-100 Calls
SPY 07/02 $313-314 Calls
AVA 09/20 $40-45 Calls
NWN 09/20 $ 60-65 Calls 

Extended Watchlist:
WNDW, TMXN, STTH, BYOC, HEME, SPOM

Blue Horseshoe Stocks: Z Follow-Up & More

Zillow Group, Inc. Z

First thing’s first- we wanted to update our readers once again on the Zillow calls we made on Tuesday morning. We designated the Z Weekly $48-49 Calls as our targets and after a good first day, the stock continued its upward climb during yesterday’s session.

That move alloted for even further increases on our observed range of contracts, and pushed our two-day observed swings well into multi-bag territory:

$48 Calls – Range: 1.30-3.55 – Max Gain: 173%
$48.50 Calls – Range: 1.10-2.60 – Max Gain: 136%
$49 Calls – Range: .80-2.60 – Max Gain: 225%
________

Fresh Ideas:
YELP Weekly $43-44.50 Calls
ROKU Weekly $52-53.50 Calls

Healthmed Services, Inc HEME

It isn’t often these days that we target a subpenny OTC stock. Our long-time followers know that those were our primary focus when we started out exactly 7 years ago this past Tuesday. We did very well in that capacity for many years, despite having recently shifted focus more to fast-paced options trading.

Of any of the sectors we ever covered in the OTC space, cannabis has certainly been the most exciting, and continues to be one of our primary interests on the stock side of things to this day.

That’s why we just want to put HEME on our readers radars. Despite being listed as defunct on OTC Markets, the company recently revealed its intentions to get things back on track and enter the marijuana space.

According to its updated website, HEME is presently acquiring, leasing and licensing growers for the cultivation, production and distribution of cannabis and cannabis-related products in southern California. The project site has state Highway access, water and local transportation are convenient and accessible, and the City government has designated the project site – legal planting zoning.

We are going to keep tabs on the company’s progress toward not only developing in this new direction, but also coming current on its reporting.

Extended Watchlist:
WIN, UPL, TIVO, ANGI, CVNA, RDHL,